I am a
Home I AM A Search Login

Papers of the Week

2019 Sep 05

N Engl J Med



Trial of SAGE-217 in Patients with Major Depressive Disorder.


Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ
N Engl J Med. 2019 Sep 05; 381(10):903-911.
PMID: 31483961.


Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.